Gene Therapy For Neurodegenerative Disorders
Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
1 . A self-complementary adeno-associated virus (scAAV) vector comprising a polynucleotide encoding a protein that modulates motor function in a subject with a motor neuron disorder.
2 . The scAAV vector of claim 1 , wherein the motor neuron disorder is selected from spinal muscular atrophy (SMA), amytrophic lateral sclerosis (ALS), spinal bulbar muscular atrophy, spinal cerebellar ataxia, primary lateral sclerosis (PLS), or traumatic spinal cord injury.
3 . The scAAV vector of claim 2 , wherein the motor neuron disorder is SMA.
4 . The scAAV vector of claim 3 , wherein the polynucleotide encodes a survival motor neuron (SMN) protein.
5 . The scAAV vector of claim 4 , wherein the SMN protein is encoded by human SMN-1.
6 . The scAAV vector of claim 5 , wherein the SMN protein comprises an amino acid sequence with at least 90% sequence identity to the sequence depicted in FIG. 9 B .
7 . The scAAV vector of claim 6 , wherein the SMN protein comprises an amino acid sequence as depicted in FIG. 9 B .
8 . A recombinant AAV virion, comprising the scAAV vector of claim 1 .
9 . A composition comprising a recombinant AAV virion according to claim 8 and a pharmaceutically acceptable excipient.
10 . A method of modulating motor function in a subject with a motor neuron disorder comprising administering a therapeutically effective amount of the composition of claim 9 to cells of the subject.
11 . A method of providing SMN protein to a subject with spinal muscular atrophy (SMA) comprising administering a recombinant AAV virion comprising an AAV vector according to claim 4 to cells of a subject in need thereof.
12 . The method of claim 10 , wherein the composition is administered via administration into at least one region of the deep cerebellar nuclei of the cerebellum.
13 . The method of claim 10 , wherein the composition is administered via direct spinal cord injection.
14 . The method of claim 10 , wherein the composition is administered via intracerebroventricular injection
15 . The method of claim 14 , wherein the composition is administered into at least one cerebral lateral ventricle.
16 . The method of claim 10 , wherein the composition is administered via both intracerebroventricular injection and direct spinal cord injection.
17 . The method of claim 10 , wherein the composition is administered via intrathecal injection.
18 . Use of a recombinant AAV virion according to claim 8 in the manufacture of a medicament for modulating motor function in a subject with a motor neuron disorder.
19 . Use of a recombinant AAV virion comprising an AAV vector according to claim 4 in the manufacture of a medicament for providing SMN protein to the cells of a subject with spinal muscular atrophy (SMA).